Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Open Label, Pivotal Study to Evaluate the Efficacy and Safety of HQP1351 in CML CP Patients Who Are Resistant and/or Intolerant to First- and Second-Generation Tyrosine Kinase Inhibitors

Next Previous
Search
Trial Profile

A Phase 2, Randomized, Open Label, Pivotal Study to Evaluate the Efficacy and Safety of HQP1351 in CML CP Patients Who Are Resistant and/or Intolerant to First- and Second-Generation Tyrosine Kinase Inhibitors

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olverembatinib (Primary) ; Dasatinib; Hydroxycarbamide; Imatinib; Interferon; Nilotinib; Omacetaxine mepesuccinate
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Ascentage Pharma

    • Most Recent Events

    • 03 Mar 2025 Status changed from active, no longer recruiting to completed.
    • 13 Dec 2023 Results (As of October 17, 2023, n=144) presented in the Ascentage Pharma Media Release.
    • 13 Dec 2023 According to a Ascentage Pharma media release, data from the study were presented in an Oral Presentation at the 65th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, CA, the United States.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top